Hetero Biopharma Profile
Key Indicators
- Authorised Capital ₹ 166.00 Cr
- Paid Up Capital ₹ 150.05 Cr
- Company Age 8 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 166.43 Cr
- Revenue Growth 2.02%
- Profit Growth -2.10%
- Ebitda -17.95%
- Net Worth 53.31%
- Total Assets 20.11%
About Hetero Biopharma
Hetero Biopharma Limited (HBL) is a Public Limited Indian Non-Government Company incorporated in India on 14 September 2016 (Eight years and four months 19 days old ). Its registered office is in Rangareddy, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 166.00 Cr and a paid-up capital of Rs 150.05 Cr.
The company currently has active open charges totaling ₹166.43 Cr.
The Key Managerial Personnel (KMP) at Hetero Biopharma Limited India are Janardhan Katersala as COMPANY SECRETARY and Divyanshu Patidar as Cfo. Parthasaradhi Bandi, Chandra Tumuluru, Bhavesh Pujara, and Two other members serve as directors at the Company.
Company Details
-
Location
Rangareddy, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24290TG2016PLC111946
-
Company No.
111946
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
14 Sep 2016
-
Date of AGM
23 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Hetero Biopharma?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Janardhan Katersala | Company Secretary | 29-Dec-2023 | Current |
| Divyanshu Patidar | CFO | Current |
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parthasaradhi Bandi
|
Director | 14-Sep-2016 | Current |
|
Chandra Tumuluru
|
Director | 16-Jul-2021 | Current |
|
Bhavesh Pujara
|
Director | 08-Jul-2024 | Current |
|
Govindaraju Bhavani
|
Director | 26-Aug-2022 | Current |
|
Bandi Vamsikrishna
|
Director | 25-Mar-2021 | Current |
Financial Performance of Hetero Biopharma.
Hetero Biopharma Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.02% increase. The company also saw a slight decrease in profitability, with a 2.1% decrease in profit. The company's net worth Soared by an impressive increase of 53.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hetero Biopharma?
In 2023, Hetero Biopharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Hetero Marbles Private LimitedChandra Tumuluru and Bandi Vamsikrishna are mutual person
-
Hetero Labs LimitedParthasaradhi Bandi, Govindaraju Bhavani and 1 more are mutual person
-
Hetero Drugs Limited
Parthasaradhi Bandi and Bandi Vamsikrishna are mutual person
-
Hetero Plasma Sciences Private Limited
Janardhan Katersala, Divyanshu Patidar and 1 more are mutual person
-
Hetero Wind Power Limited
Bandi Vamsikrishna is a mutual person
-
Hetero Med Solutions Limited
Bandi Vamsikrishna is a mutual person
Charges (Loans)
₹166.43 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 166.43 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 14 Feb 2024 | Others | ₹2.50 M | Open |
| 20 Feb 2023 | Others | ₹2.00 M | Open |
| 07 Jun 2022 | Others | ₹9.79 M | Open |
| 14 Sep 2021 | Others | ₹165.00 Cr | Open |
How Many Employees Work at Hetero Biopharma?
Hetero Biopharma has a workforce of 526 employees as of Sep 20, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hetero Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hetero Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
